ANTI-HYPOXIC AND ANTI-ISCHEMIC DRUG

A találmány tárgya olyan metabolikus komponensen alapuló gyógyszerkülönösen új gyógyszer készítmény, amely növeli a test, a szervek és aszövetek tűrőképességét a hypoxiás és ischaemiás hatásokkal szembenazáltal, hogy védi az energiaellátó rendszer homeostasisát ésmegszünteti annak zavarait, valamint teljesen helyreállítja a hypoxiásés ischaemiás károsodást szenvedett sejteket. A gyógyszerjellegzetessége, hogy tartalmaz még hozzáadott koenzimeket is. Ó The invention relates to the field of medicine and more particularly to novel drugs which improve the resistance of human organism and tissues to hypoxia and ischemia by preventing and blocking homeostasis disorders of the energy system and allowing full recovery of the homeostasis pathologic condition in case of ischemic and hypoxic lesions of the cell. According to the invention, an anti-hypoxic and anti-anginal drug contains a metabolic ingredient (Energostim) and coferments such as flavin adenine dinucleotide (or its precursor flavin mononucleotide or riboflavin mutually transforming in the organism or a derived product of riboflavin, the benzoflavin, which is also transformed into desired flavins) as well as the coferment Q10 (the ubiquinone). The drug has the following composition: coferments: 1,2 -20 %; metabolic ingredient: 65,5 - 98,8 %. The drug of this invention may be-widely used to strengthen the resistance of the human body and tissues to the hypoxia, to improve the working capacity in extreme conditions, in the space and in deep water as well as for the treatment of brain ischemia and of myocardial infarction and of other ischemic and hypoxic conditions of tissues and organs.